OpenAI Acquires Orchestra Bio to Integrate Drug Development Operations with Life Sciences AI
Sign in✓ Signed in
OpenAI announced the acquisition of Orchestra Bio, a software platform that coordinates the operational complexities of drug development for biopharma teams. The acquisition integrates a specialized R&D operations platform with OpenAI's Rosalind, its suite of reasoning models and tools designed for life sciences research, to accelerate the path from target discovery to regulatory approval.
Continue reading
The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.
Already purchased? Sign in✓ Signed in — this article isn’t included in your current plan.
Unlocking the full article...